Biotech Stocks in “Total Eclipse” as Financial Pressures Mount
More than a year after biotech stock indices peaked, the markets are worse than ever.…
15/03/2022 - 6 minutes
Forbion Capital Partners
European Biotech Investors Cap Off Record Year in Fundraising
The year 2021 is closing with a biotech investment rush as Eir Ventures, Apollo Health…
10/12/2021 - 4 minutes
Forbion Raises €185M to Fuel Late-Stage European Biotechs
The Dutch life sciences venture capital firm Forbion has bagged €185M in the first closing…
13/07/2020 - 3 minutes
Anti-Inflammatory Treatments Get €40M Boost in Series B
A Series B funding round has whipped up €40M for the Irish company Inflazome. This…
19/11/2018 - 2 minutes
Update: Forbion’s Life Science Fund Tops Goal by €90M
Update: The European venture capital firm Forbion closed fundraising for it's fourth life sciences fund…
01/10/2018 - 2 minutes
British Biotech Raises £29M Round to Fight Lung Disease
Enterprise Therapeutics has raised a substantial Series B financing round to bring its treatments for…
12/04/2018 - 2 minutes
New Dutch Biotech Sails Straight into Phase II with €25M Series A to Treat NASH
NorthSea Therapeutics has been founded in the Netherlands to develop a drug against NASH, a…
12/12/2017 - 3 minutes
“We’re at a second revolution in cancer therapy” – Experts discuss the Future of Oncology at Refresh
A panel of experts in immuno-oncology discussed the challenges and opportunities to develop therapies that can…
20/06/2017 - 2 minutes
Meet the co-developer of the first commercial mAb and gene therapy
Sander van Deventer is now a managing partner at Forbion after playing a critical role…
08/05/2017 - 5 minutes
Why did Biotech Beat Pharma to Bring the First Gene Therapy to Market?
Pharma would seemingly best biotech in any competition. A few CEOs explain why it left the honor…
28/03/2017 - 5 minutes
Swiss Parkinson’s Biotech raises Massive €29M in Series B from Top European VCs
Top European VCs have invested €29M in Prexton Therapeutics to support two Phase II trials…
07/02/2017 - 2 minutes
Not to be Underestimated: What’s the Hype around NASH?
Since 2014, investment in Non-Alcoholic SteatoHepatitis (NASH) has taken off with a fervor reminiscent of…
07/02/2017 - 10 minutes
